ClinicalTrials.gg
Active, not recruitingNCT07185776Updated Mar 5, 2026

A Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

A Phase 2 interventional study of HRS-5632 Injection and HRS-5632 Injection Placebo in Lipoprotein Disorder, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. Active, not recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
203
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The main purpose of this study is to evaluate the efficacy and safety of HRS-5632 in adult participants with elevated Lipoprotein(a) (Lp(a)) at high risk for cardiovascular events.

02

Conditions studied

  • Lipoprotein Disorder
03

In context

Lead sponsor

Fujian Shengdi Pharmaceutical Co., Ltd. is the lead sponsor of 66 studies on the registry; 24 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Understanding the specific procedures of the trial, voluntarily participating in this trial, and providing written ;
  2. Being at least 18 years of age on the day of signing the informed consent form;
  3. (BMI) within the range of 18.5 to 40 kg/m² (inclusive of boundary values);
  4. Participants must be at high risk of cardiovascular events, defined as individuals diagnosed with Atherosclerotic Cardiovascular Disease (ASCVD) and those at moderate risk or high risk for ASCVD;
  5. Based on clinical practice, participants receiving the following medications must be receiving a stable regimen prior to screening or randomization and expected to remain on a stable regimen at the end of the treatment follow-up period:

    1. Lipid-lowering drugs (statins, cholesterol absorption inhibitors, prescription-dose niacin, fibrates, fish oil or other omega-3 fatty acid-containing products, including over-the-counter [OTC] preparations) must be receiving a stable regimen for ≥ 8 weeks prior to randomization; PCSK9 monoclonal antibodies must be receiving a stable regimen for ≥ 12 weeks prior to screening;
    2. Testosterone, estrogen, anti-estrogen/anti-androgen, progestin, selective estrogen receptor modulator, or growth hormone must be receiving a stable regimen for ≥ 4 weeks prior to screening;
  6. Participants (including their partners) are willing to voluntarily use highly effective measures from the time of signing the informed consent form until 1 year after the last administration of the study drug; female participants must have a negative blood pregnancy test and must not be breastfeeding;
  7. Willing and able to comply with all the provisions of the protocol, including demonstrating the ability to adhere to study procedures prior to random assignment.

Exclusion criteria

Exclusion Criteria:

  1. Any of the following events occurring within 3 months prior to screening or between screening and randomization, or other events considered by the investigator to indicate clinical instability: major cardiac or non-cardiac surgery; coronary, carotid, or peripheral arterial revascularization; stroke or , myocardial infarction or unstable angina, acute limb ischemia, and uncontrolled arrhythmias requiring treatment;
  2. Cardiac, cerebrovascular, or peripheral arterial surgery or coronary revascularization planned or anticipated during the trial after randomization;
  3. A history of hemorrhagic stroke or other major bleeding (e.g., hemophilia, von Willebrand disease, coagulation factor deficiency), or a hemorrhagic stroke or other major bleeding event (fatal; major organ bleeding; resulting in a rapid, short-term decrease in or blood transfusion) occurring between the screening visit and the randomization visit;
  4. Patients with an indication for anticoagulation at screening but not receiving anticoagulation therapy, such as patients with atrial fibrillation or flutter or those undergoing aortic valve replacement;
  5. History of any organ system within 5 years prior to screening (excluding cured basal cell or squamous cell skin cancer, non-invasive stage 0 cervical cancer, non-invasive stage 0 prostate cancer, or ductal carcinoma in situ of the breast), or a history of any organ system malignancy diagnosed between the screening visit and the randomization visit, regardless of whether there is evidence of local recurrence or ;
  6. A history of a disease that significantly affects lipid levels, such as nephrotic syndrome, severe liver disease, or Cushing's syndrome;
  7. Uncontrolled type 1 or type 2 diabetes (including diabetic ketoacidosis or hyperglycemic hyperosmolar state) within 6 months prior to screening, or > 8.0% at screening (secondary confirmation is permitted);
  8. History of acute kidney injury within 12 months prior to screening;
  9. Uncontrolled hyperthyroidism or hypothyroidism at screening or before randomization;
  10. Active infection requiring systemic antiviral or antibacterial medication before randomization;
  11. (NYHA) class III-IV heart function or a most recently measured (LVEF) \<30% at screening or before randomization;
  12. At screening or before randomization, patients, as determined by the investigator, have a major medical condition that is currently unstable and not adequately controlled, such as hematologic disease, renal disease, metabolic or endocrine dysfunction, gastrointestinal disease, chronic disease or infection, unstable mental health disorder, or are recovering from major surgery;
  13. Long-term continuous or repeated use of systemic within 3 months prior to screening (excluding local use, such as intra-articular, nasal, inhaled, topical, etc.; long-term continuous means ≥ 7 days; repeated means cumulative use ≥ 3 times);
  14. Lipoprotein apheresis within 3 months prior to screening, or plans to undergo such treatment during the study;
  15. Patients who are allergic to the active ingredient or any of HRS-5632;
  16. Uncontrolled hypertension (sitting systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg) before randomization;
  17. \< 30 ml/min/1.73 m² (calculated using the CKD-EPI 2009 formula) at screening or before randomization, or current dialysis;
  18. (ALT), aspartate aminotransferase (AST), or gamma-glutamyltransferase (GGT) more than 3 times the (ULN), or total more than 1.5 times the ULN at screening or before randomization;
  19. Fasting triglycerides ≥ 5.6 mmol/L before randomization;
  20. infection (HIV-Ab positive), virus infection (HCV-RNA positive), Treponema pallidum infection (Treponema pallidum antibody positive), or virus infection (HBsAg or HBV-DNA positive) at screening or before randomization;
  21. Creatine kinase (CK) levels more than 3 times the ULN before randomization;
  22. Thyroid-stimulating hormone (TSH) levels below the lower limit of normal (LLN) or more than 1.5 times the ULN before randomization;
  23. Significant abnormalities in laboratory test indicators at screening or before randomization, deemed unsuitable for participation in this study by the investigator;
  24. Recent history (within the past year) of drug or alcohol abuse or dependence;
  25. Pregnant or breastfeeding women;
  26. Participants who have participated in any drug or medical device clinical trial within 3 months prior to screening (participation in a clinical trial is defined as the participant receiving treatment with the drug/device), or who have been exposed to the investigational drug for less than 5 half-lives before screening, whichever is longer;
  27. Participants who, as determined by the investigator, are noncompliant or have any other factors that make them unsuitable for participation in the trial, including but not limited to participation that would place the participant at unacceptable risk or could interfere with study evaluations, procedures, or completion.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
203 participants (actual)

Study arms

  • Experimental
    HRS-5632 Dose 1 Group

    Drug: HRS-5632 Injection

  • Experimental
    HRS-5632 Dose 2 Group

    Drug: HRS-5632 Injection

  • Experimental
    HRS-5632 Dose 3 Group

    Drug: HRS-5632 Injection

  • Experimental
    HRS-5632 Dose 4 Group

    Drug: HRS-5632 Injection

  • Placebo comparator
    HRS-5632 Placebo Group

    Drug: HRS-5632 Injection Placebo

Interventions

  • DrugHRS-5632 Injection

    HRS-5632 injection.

  • DrugHRS-5632 Injection Placebo

    HRS-5632 injection placebo.

06

What researchers measure

Primary outcomes

  1. The percent change from the baseline in Lipoprotein (a) (Lp(a)).

    Time frame: From baseline to Day 360.

Secondary outcomes

  1. The percentage of all reported adverse events (AEs).

    Time frame: From Day 1 to Day 540.

  2. The percentage of all reported serious adverse events (SAEs).

    Time frame: From Day 1 to Day 540.

  3. The percentage of treatment-related adverse events.

    Time frame: From Day 1 to Day 540.

  4. The percentage of treatment-related serious adverse events.

    Time frame: From Day 1 to Day 540.

  5. The percentage of participants achieving Lipoprotein(a) (Lp(a)) < 125 Nanomole/Liter (nmol/L).

    Time frame: Day 540.

  6. The percentage of participants achieving Lipoprotein(a) (Lp(a)) < 75 Nanomole/Liter (nmol/L).

    Time frame: Day 540.

  7. The plasma concentration of HRS-5632.

    Time frame: From Day 1 to Day 540.

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Apr 2027, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2025
First posted
Sep 22, 2025
StartActual
Oct 21, 2025
Primary completionEst.
Apr 2027
CompletionEst.
Oct 2027
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07185776
Responsible party
Sponsor
First posted
Sep 22, 2025
Start date
Oct 21, 2025
Primary completion
Apr 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Mar 5, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion